The siRNA cocktail targeting VEGF and HER2 inhibition on the proliferation and induced apoptosis of gastric cancer cell

被引:37
作者
Liu, Kun [1 ]
Chen, Honglin [2 ]
You, Qingsheng [1 ]
Shi, Hai [1 ]
Wang, Zhiwei [1 ]
机构
[1] Nantong Univ, Dept Cardiothorac Surg, Affiliated Hosp, Nantong 226001, Jiangsu, Peoples R China
[2] Nantong Univ, Sch Nursing, Nantong 226001, Jiangsu, Peoples R China
关键词
siRNA; siRNA cocktail; VEGF; HER2; Gastric cancer; SGC-7901; SMALL INTERFERING RNA; CLINICAL-SIGNIFICANCE; PROGNOSTIC-FACTOR; EXPRESSION; GENE; BEVACIZUMAB; HER-2/NEU; THERAPY; GROWTH; MODEL;
D O I
10.1007/s11010-013-1850-0
中图分类号
Q2 [细胞生物学];
学科分类号
071013 [干细胞生物学];
摘要
The aim of this study was to investigate the inhibitory effect of a siRNA cocktail targeting Vascular endothelial growth factor (VEGF) and Human epidermal growth factor receptor 2 (HER2) on cell proliferation, induced apoptosis and the expression of VEGF and HER2 in human gastric carcinoma cell. The silencing rate of pre-designed siRNAs that targeted VEGF and HER2 was detected by Real-time Quantitative PCR (RT-QPCR) analysis. Furthermore, the best silencing siRNA that targeted VEGF and HER2 was prepared as a cocktail to co-knockdown VEGF and HER2 expression at both mRNA and protein levels which were detected by RT-QPCR and Western blot analysis. Cell proliferation inhibition rates were determined by CCK8 assay. The effect of siRNA cocktail on cell apoptosis was determined by flow cytometry. The migration inhibition of siRNA cocktail was analyzed by wound-healing assay. The ability of VEGF to induce endothelial cells to proliferate was examined in HUVECs by the method of tube formation assay. The pre-designed siRNAs could inhibit VEGF and HER2 mRNA level. siRNA cocktail, and co-downregulation of VEGF and HER2 result in significant inhibition of gastric cancer growth and migration in vitro. The inhibition of VEGF and HER2 expressions can induce apoptosis of SGC-7901 cells.
引用
收藏
页码:117 / 124
页数:8
相关论文
共 34 条
[1]
Safety profile of RNAi nanomedicines [J].
Barros, Scott A. ;
Gollob, Jared A. .
ADVANCED DRUG DELIVERY REVIEWS, 2012, 64 (15) :1730-1737
[2]
OVEREXPRESSION OF HER-2 NEU IN ENDOMETRIAL CANCER IS ASSOCIATED WITH ADVANCED STAGE DISEASE [J].
BERCHUCK, A ;
RODRIGUEZ, G ;
KINNEY, RB ;
SOPER, JT ;
DODGE, RK ;
CLARKEPEARSON, DL ;
BAST, RC .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 164 (01) :15-21
[3]
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients [J].
Cappuzzo, F ;
Varella-Garcia, M ;
Shigematsu, H ;
Domenichini, I ;
Bartolini, S ;
Ceresoli, GL ;
Rossi, E ;
Ludovini, V ;
Gregorc, V ;
Toschi, L ;
Franklin, WA ;
Crino, L ;
Gazdar, AF ;
Bunn, RA ;
Hirsch, FR .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5007-5018
[4]
VEGF as a key mediator of angiogenesis in cancer [J].
Carmeliet, P .
ONCOLOGY, 2005, 69 :4-10
[5]
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases [J].
Carmeliet, Peter ;
Jain, Rakesh K. .
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (06) :417-427
[6]
Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis [J].
Chen, Jing ;
Li, Tao ;
Wu, Yuanyuan ;
He, Lijun ;
Zhang, Li ;
Shi, Tieliu ;
Yi, Zhengfang ;
Liu, Mingyao ;
Pang, Xiufeng .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (12) :1799-1812
[7]
Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines [J].
Choudhury, A ;
Charo, J ;
Parapuram, SK ;
Hunt, RC ;
Hunt, DM ;
Seliger, B ;
Kiessling, R .
INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (01) :71-77
[8]
The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis [J].
Eceles, SA .
JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, 2001, 6 (04) :393-406
[9]
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target [J].
Gravalos, C. ;
Jimeno, A. .
ANNALS OF ONCOLOGY, 2008, 19 (09) :1523-1529
[10]
The Business of RNAi Therapeutics in 2012 [J].
Haussecker, Dirk .
MOLECULAR THERAPY-NUCLEIC ACIDS, 2012, 1